ValuEngine downgraded shares of IPSEN S A/S (OTCMKTS:IPSEY) from a hold rating to a sell rating in a research note issued to investors on Monday morning, ValuEngine reports.

Separately, JPMorgan Chase & Co. set a $90.00 target price on Duke Energy and gave the company a hold rating in a report on Monday, May 20th.

IPSEY traded up $0.32 during midday trading on Monday, reaching $33.17. The company’s stock had a trading volume of 222 shares, compared to its average volume of 1,413. The stock has a market capitalization of $11.10 billion, a PE ratio of 19.06, a P/E/G ratio of 1.22 and a beta of 0.49. The firm has a fifty day simple moving average of $32.08. IPSEN S A/S has a twelve month low of $27.58 and a twelve month high of $44.60.


Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.

Read More: How to interpret Moving Average Convergence Divergence (MACD)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with's FREE daily email newsletter.